Inclusion Criteria:

1. Women aged from 18 to 65 years;

2. Histologically proven invasive unilateral breast cancer (regardless of the type);

3. Initial clinical condition compatible with complete initial resection;

4. No residual macro or microscopic tumor after surgical excision;

5. Beginning of chemotherapeutic treatment no later than day 42 after the initial
surgery;

6. Node positive disease (positive sentinel node or positive axillary clearance) (N+) or
node negative disease (N-) with the following criteria : SBR II / III and pT > 5 mm;

7. Patient presenting one of the following criteria (reviewed before randomization by
referent pathologist):

Triple negative （ER-PR-Her-2-） Hormone receptor negativity is defined as ER<10%,
PR<10% (IHC), HER2 negativity is defined as IHC 0-1+, or [IHC 2+ and FISH or CISH
negative].

8. No clinically or radiologically detectable metastases (M0);

9. No peripheral neuropathy > 1;

10. WHO Performance status (ECOG) of 0 or 1;

11. Adequate recovery from recent surgery (at least one week must have elapsed from the
time of a minor surgery (excluding breast biopsy); at least three weeks for major
surgery);

12. Adequate hematological function (neutrophil count ³ 2x109/l, platelet count ³ 100x
109/l, Hemoglobin > 9 g/dl);

13. Adequate hepatic function: ASAT and ALAT £ 1.5 ULN alkaline phosphatases £ 2.5
ULN,total bilirubin £ 1,5 ULN;

14. Adequate renal function: serum creatinine £ 1.5 ULN;

15. Patients accepting contraception intake during the overall length of treatment if of
childbearing potential;

16. Adequate cardiac function, LEVF value > 50% by Muga scan or echocardiography;

17. Signed written informed consent.

Exclusion Criteria:

1. Bilateral breast cancer or patient with controlateral DCIS;

2. Any metastatic impairment, including homolateral sub-clavicular node
involvement,regardless of its type;

3. Any tumor ³ T4a (UICC1987) (cutaneous invasion, deep adherence, inflammatory breast
cancer);

4. ER+ or PR+ or Her-2 overexpression

5. Any clinically or radiologically suspect and non-explored damage to the controlateral
breast;

6. Any chemotherapy, hormonal therapy or radiotherapy before surgery;

7. Previous cancer (excepted cutaneous baso-cellular epithelioma or uterin peripheral
ephitelioma) in the preceding 5 years, including invasive controlateral breast
cancer;

8. Patients already included in another therapeutic trial involving an experimental
drug;

9. Patients with other concurrent severe and/or uncontrolled medical disease or
infection which could compromise participation in the study;

10. LEVF < 50% (MUGA scan or echocardiography);

11. Clinically significant cardiovascular disease (e.g. unstable angina, congestive heart
failure, uncontrolled hypertension (>150/90), myocardial infarction or cerebral
vascular accidents) within 6 months prior to randomization;

12. Known prior severe hypersensitivity reactions to agents containing Cremophor EL;

13. Women of childbearing potential who are unwilling or unable to use an acceptable
method to avoid pregnancy for the entire study period and up to 8 weeks after
treatment completion;

14. Women who are pregnant or breastfeeding. Adequate birth control measures should be
taken during study treatment phase;

15. Women with a positive pregnancy test en enrollment or prior to study drug
administration;

16. Patients with any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule;
those conditions should be discussed with the patient before registration in the
trial;

17. Individual deprived of liberty or placed under the authority of a tutor.